IQVIA (NYSE:IQV) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of IQVIA (NYSE:IQV – Get Rating) in a report released on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Several other research firms have also commented on IQV. SVB Leerink reiterated an “outperform” rating on shares of IQVIA in a research report on Friday, January 27th. JPMorgan Chase & Co. lifted their price target on IQVIA from $257.00 to $263.00 and gave the stock an “overweight” rating in a research report on Monday, February 27th. Citigroup lowered IQVIA from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $275.00 to $245.00 in a research report on Thursday, November 17th. Cowen began coverage on shares of IQVIA in a research note on Tuesday, December 6th. They issued an “outperform” rating for the company. Finally, Robert W. Baird decreased their price objective on shares of IQVIA from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Friday, January 13th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $256.27.

IQVIA Trading Down 2.7 %

Shares of IQV stock opened at $195.27 on Thursday. IQVIA has a 52-week low of $165.75 and a 52-week high of $254.94. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.89 and a current ratio of 0.89. The firm has a market capitalization of $36.35 billion, a PE ratio of 34.20, a PEG ratio of 1.93 and a beta of 1.40. The stock has a fifty day simple moving average of $219.44 and a two-hundred day simple moving average of $209.00.

IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings results on Friday, February 10th. The medical research company reported $2.78 EPS for the quarter, topping the consensus estimate of $2.76 by $0.02. The company had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.71 billion. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the business posted $2.42 earnings per share. On average, analysts predict that IQVIA will post 9.51 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 14th. The shares were sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the sale, the insider now owns 17,053 shares of the company’s stock, valued at approximately $3,922,190. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 14th. The shares were sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the sale, the insider now owns 17,053 shares of the company’s stock, valued at approximately $3,922,190. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction dated Thursday, February 16th. The shares were sold at an average price of $225.61, for a total transaction of $1,003,062.06. Following the sale, the insider now directly owns 1,973 shares of the company’s stock, valued at approximately $445,128.53. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Institutional Trading of IQVIA

Several hedge funds have recently made changes to their positions in the company. State Street Corp grew its stake in shares of IQVIA by 3.8% in the 2nd quarter. State Street Corp now owns 8,622,096 shares of the medical research company’s stock valued at $1,870,909,000 after buying an additional 315,751 shares during the period. Alliancebernstein L.P. lifted its holdings in IQVIA by 20.1% during the 3rd quarter. Alliancebernstein L.P. now owns 5,157,158 shares of the medical research company’s stock worth $934,167,000 after buying an additional 862,222 shares in the last quarter. Bishop Rock Capital L.P. raised its holdings in shares of IQVIA by 14,549.4% in the 2nd quarter. Bishop Rock Capital L.P. now owns 4,050,552 shares of the medical research company’s stock valued at $18,667,000 after purchasing an additional 4,022,902 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of IQVIA by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 3,722,660 shares of the medical research company’s stock valued at $761,318,000 after purchasing an additional 90,188 shares in the last quarter. Finally, Lazard Asset Management LLC grew its position in shares of IQVIA by 1.0% in the 4th quarter. Lazard Asset Management LLC now owns 2,844,533 shares of the medical research company’s stock valued at $582,814,000 after buying an additional 29,537 shares during the last quarter. Hedge funds and other institutional investors own 86.20% of the company’s stock.

About IQVIA

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.